Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-12-01
|
| Series: | BMJ Open Respiratory Research |
| Online Access: | https://bmjopenrespres.bmj.com/content/10/1/e001472.full |
| _version_ | 1797370970850197504 |
|---|---|
| author | Brian J Lipworth Rory Chan |
| author_facet | Brian J Lipworth Rory Chan |
| author_sort | Brian J Lipworth |
| collection | DOAJ |
| description | Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with poor asthma control and type 2 inflammation.Methods 21 GINA-defined severe asthma patients who were treated with benralizumab and who had baseline oscillometry-defined SAD were included in this study. Here, SAD was diagnosed only if patients satisfied both R5–R20≥0.10 kPa/L/s and AX≥1.0 kPa/L. The mean duration of follow-up between pre-benralizumab versus post-benralizumab clinical measurements was 8 months.Results Mean values for FEV1% and FVC% but not FEF25%–75% significantly increased following benralizumab, along with significant reductions in Asthma Control Questionnaire (ACQ). There were no significant improvements in R5–R20, X5 or AX, while the mean (SEM) PBE count fell to 23 (14) cells/µL. In a responder analysis, n=8/21 and n=12/21 patients experienced improvements exceeding biological variability of 0.04 kPa/L/s and 0.39 kPa/L in R5–R20 and AX, respectively, in severe asthma. N=10/21, n=10/21 and n=11/21 patients experienced improvements in FEV1, FEF25–75 and FVC exceeding biological variability of 150 mL, 0.210 L/s and 150 mL, respectively. In contrast, n=15/21 patients experienced an improvement in ACQ greater than minimal clinical important difference of 0.5 units.Conclusion Eosinophil depletion with benralizumab improves spirometry and asthma control but does not improve spirometry-measured or oscillometry-measured SAD in severe asthma in a real-life setting. |
| first_indexed | 2024-03-08T18:13:04Z |
| format | Article |
| id | doaj.art-c9b8ac08f5ef416f8053679d5d2c5b38 |
| institution | Directory Open Access Journal |
| issn | 2052-4439 |
| language | English |
| last_indexed | 2024-03-08T18:13:04Z |
| publishDate | 2023-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Respiratory Research |
| spelling | doaj.art-c9b8ac08f5ef416f8053679d5d2c5b382024-01-01T02:25:08ZengBMJ Publishing GroupBMJ Open Respiratory Research2052-44392023-12-0110110.1136/bmjresp-2022-001472Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthmaBrian J Lipworth0Rory Chan1Scottish Centre for Respiratory Research, University of Dundee School of Medicine, Dundee, UKScottish Centre for Respiratory Research, University of Dundee School of Medicine, Dundee, UKIntroduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though the latter correlates better with poor asthma control and type 2 inflammation.Methods 21 GINA-defined severe asthma patients who were treated with benralizumab and who had baseline oscillometry-defined SAD were included in this study. Here, SAD was diagnosed only if patients satisfied both R5–R20≥0.10 kPa/L/s and AX≥1.0 kPa/L. The mean duration of follow-up between pre-benralizumab versus post-benralizumab clinical measurements was 8 months.Results Mean values for FEV1% and FVC% but not FEF25%–75% significantly increased following benralizumab, along with significant reductions in Asthma Control Questionnaire (ACQ). There were no significant improvements in R5–R20, X5 or AX, while the mean (SEM) PBE count fell to 23 (14) cells/µL. In a responder analysis, n=8/21 and n=12/21 patients experienced improvements exceeding biological variability of 0.04 kPa/L/s and 0.39 kPa/L in R5–R20 and AX, respectively, in severe asthma. N=10/21, n=10/21 and n=11/21 patients experienced improvements in FEV1, FEF25–75 and FVC exceeding biological variability of 150 mL, 0.210 L/s and 150 mL, respectively. In contrast, n=15/21 patients experienced an improvement in ACQ greater than minimal clinical important difference of 0.5 units.Conclusion Eosinophil depletion with benralizumab improves spirometry and asthma control but does not improve spirometry-measured or oscillometry-measured SAD in severe asthma in a real-life setting.https://bmjopenrespres.bmj.com/content/10/1/e001472.full |
| spellingShingle | Brian J Lipworth Rory Chan Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma BMJ Open Respiratory Research |
| title | Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| title_full | Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| title_fullStr | Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| title_full_unstemmed | Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| title_short | Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| title_sort | real life effects of benralizumab on airway oscillometry in severe eosinophilic asthma |
| url | https://bmjopenrespres.bmj.com/content/10/1/e001472.full |
| work_keys_str_mv | AT brianjlipworth reallifeeffectsofbenralizumabonairwayoscillometryinsevereeosinophilicasthma AT rorychan reallifeeffectsofbenralizumabonairwayoscillometryinsevereeosinophilicasthma |